Understand the source comparison
Best Glow Stack Dosage for Skin Health: Clinical vs Research Applications
Collagen Peptide (Type I/III) 500mcg subcutaneous 5–10g oral Oral for clinical; subQ for research 24–36 hours (oral), 8–12 hours (subQ) Research protocols use low-dose subcutaneous for direct fibroblast signalling; clinical protocols rely on high-dose oral for
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Collagen Peptide (Type I/III)
- 500mcg subcutaneous
- 5–10g oral
- Oral for clinical; subQ for research
- 24–36 hours (oral), 8–12 hours (subQ)
- Research protocols use low-dose subcutaneous for direct fibroblast signalling; clinical protocols rely on high-dose oral for systemic hydroxyproline availability
- GHK-Cu (Copper Peptide)
- 500mcg subcutaneous or topical
- 1–2mg topical (cream formulation)
- SubQ for research; topical for clinical
- 4–6 hours (systemic), 12–18 hours (topical in lipid carrier)
- Copper delivery drives lysyl oxidase activity. Subcutaneous research doses are 50% lower than topical because bioavailability is direct
- Matrixyl 3000 (Palmitoyl Peptides)
- 3–5% concentration topical serum
- Topical for both
- 6–8 hours (topical), 4–6 hours (subQ)
- MMP inhibition is localised. Topical application at higher concentration achieves similar dermal effects to low-dose subcutaneous with fewer systemic variables
- Vitamin C (Ascorbic Acid)
- 1g oral
- 1–2g oral or topical (L-ascorbic acid 15–20%)
- Oral for both; topical adjunct in clinical
- 30 minutes (plasma peak), 10–20 days (tissue saturation)
- Required cofactor for prolyl hydroxylase. Oral dosing saturates tissue levels; topical provides localised antioxidant protection during UV exposure
- Orthosilicic Acid
- 10mg oral (choline-stabilised)
- 10–20mg oral
- Oral for both
- 4–6 hours (urinary clearance)
- Collagen cross-linking cofactor. Enhances tensile strength of newly synthesised fibres; no dermal benefit from topical application